Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS

NCT02844049 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2016-09
Last updated
2023-11-29

Condition(s) studied

Obsessive-Compulsive Disorder

Investigational drug(s) / intervention(s)

Deep Brain Stimulation

Deep Brain Stimulation: surgical procedure

Study summary

Obsessive-Compulsive Disorder (OCD) is among the most disabling psychiatric disorders as more than 40% of patients are resistant to the standard pharmacological and psychotherapy approaches and about 10% show severe disability and require institutionalization. These resistant patients may benefit from new surgical therapeutic approaches such as Deep Brain Stimulation (DBS) using high frequency stimulation of specific cerebral regions to modulate neural networks. Although promising, these results need nevertheless to be replicated and confirmed within a larger cohort of patients and considering a different main objective, instead of clinical improvement only. Indeed, despite a positive treatment response, adaptive functioning and quality of life may continue to be negatively impacted in OCD. Thus beyond symptom reduction, health-related quality of life (QoL) represents a more important objective of a treatment, as it includes both the individual's functional status and the individual's subjective perception of the impact of the illness on the patient's life. STN DBS induces significant clinical improvement, which may not be proportional to the QoL gain. Consequently, QoL appears to be a better outcome to target in the coming studies than clinical improvement alone. THe investigators thus propose a prospective study assessing the QoL changes of resistant OCD patients under STN DBS+BMT versus Best Medical Treatment (BMT) at 12 months, in order to assess the DBS induced gain in QoL in BMT-managed patients versus BMT alone.

Eligibility

Sex
ALL
Min age
18 Years
Max age
69 Years
Healthy volunteers
No
Inclusion Criteria: * OCD for \> 5 years * YBOCS\> 25 and/or YBOCS sub-scale \>15 * GAF\< 45 * 3 or more documented SRI trials, including clomipramine (10-12 weeks at adequate dose) * SRI augmentation for \> 4 weeks with at least one antipsychotic and with one of the following: lithium, clonazepam * Adequate trial of CBT (Exposure Therapy and Response Prevention) (intolerance or \>15 sessions) * Ability to provide informed consent Exclusion Criteria: * Hoarding (if the only OCD symptom) * OCD with poor insight (BABS score \> 12) * Lifetime diagnosis of psychosis or bipolar disorder; * Substance abuse or dependence within the previous six months; * Baseline Montgomery and Asberg (MADRS) suicidality item (item 10) score \>2; * Current DSM-5 personality disorder of Cluster A (e.g., paranoid or schizotypal personality disorder) or B (e.g., borderline or antisocial personality disorder); * Brain pathology, such as moderate or marked cerebral atrophy, stroke, tumor or previous neurosurgical procedures (i.e. capsulotomy etc), history of cognitive impairment and cognitive deterioration (Addenbrooke's Cognitive Examination ACE score of \< 80). * Contra-indications to surgery, anaesthesia, or MRI * compulsory hospitalization/ care; pregnant or nursing patients

Primary outcome measure(s)

  • Assessment of the impact of DBS+BMT versus BMT alone on a measure of Quality of life in resistant OCD patients at 1-year follow-up — 1 year
    QOL assessment : scores at SF36

Trial sites (8)

FacilityCityRegionStatus
CHU Henri Mondor Créteil France Completed
University Hospital of Grenoble Michallon Grenoble France Recruiting
Chu Nice - Hopital Pasteur Nice France Recruiting
APHP La Pitié Salpêtrière Paris France Recruiting
Ghu Sainte Anne Paris France Recruiting
Universitätsklinikum Köln (AöR) Cologne Germany Recruiting
Djurfeldt Stockholm Sweden Recruiting
Hôpitaux Universitaires de Genève Geneva Switzerland Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02844049 on ClinicalTrials.gov ↗ ← All trials in France